Skip to main contentAI and Advanced
/
EMCURE · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
EM
NSE · Equity shares · Biotechnology & Drugs-61.10 · -3.07%
Emcure Pharmaceuticals EMCURE
NSE:INR 1,931.9
BSE:INR 1,929.05
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for EMCURE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,993
Day rangeINR 1,902.6 — INR 2,013
52-week rangeINR 1,260 — INR 2,048
Volume2.48 L
Market cap36,502.25
P/E32.71
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)9,203.54
Net Income (INR Cr)924.36
Rev Growth (5 Year %)8.73
EPS Growth (5 Year %)18.65
P/E Ratio32.71
Book Value203.01
EPS49.98
Price/BV9.52Computed
Research path: Interpret Emcure Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
EMCUREEmcure Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 9,612.48 | 8,232.72 | 7,806.16 |
| Cash Equivalents | 147.52 | 28.12 | 60.61 |
| Other Liabilities Total | 111.08 | 355.61 | 354.17 |
| Long Term Debt | 252.21 | 187.34 | 761.92 |
| Common Stock Total | 189.59 | 189.48 | 181.15 |
| Other Current Assets Total | 435.31 | 5.94 | 9.65 |
| Total Assets | 9,612.48 | 8,232.72 | 7,806.16 |
| Current Portof LT Debt/Capital Leases | 1,006.75 | 100.87 | 390.66 |
| Total Equity | 4,950.03 | 4,446.19 | 2,952.28 |
| Long Term Investments | 60.94 | 22.13 | 19.99 |
| Retained Earnings(Accumulated Deficit) | 4,760.44 | 3,388.59 | 2,712.52 |
| Total Common Shares Outstanding | 18.96 | 18.95 | 18.91 |
| Tangible Book Valueper Share Common Eq | 203.01 | 184.67 | 109.25 |
| Goodwill Net | 414.26 | 367.78 | 378.69 |
| Total Liabilities | 4,662.45 | 3,786.54 | 4,853.88 |
| Total Debt | 1,521.24 | 1,022.75 | 2,334.97 |
| Short Term Investments | 68.74 | 85.13 | 348.39 |
| Cashand Short Term Investments | 216.26 | 240.66 | 517.39 |
| Total Receivables Net | 2,562.66 | 2,288.13 | 2,113.34 |
| Deferred Income Tax | 98 | 120.03 | 137.42 |
| Accounts Receivable-Trade Net | 2,562.66 | 2,002.92 | 1,873.48 |
| Property/Plant/Equipment Total-Net | 2,490.82 | 2,427.12 | 2,397.21 |
| Minority Interest | 26.64 | 195.37 | 169.48 |
| Total Current Liabilities | 3,912.24 | 2,668.27 | 3,210.47 |
| Total Inventory | 2,397.87 | 1,931.81 | 1,525.1 |
| Accounts Payable | 1,807.77 | 1,479.58 | 1,309.37 |
| Other Currentliabilities Total | 1,097.73 | 413.72 | 355.41 |
| Total Long Term Debt | 514.49 | 447.25 | 982.34 |
| Intangibles Net | 686.84 | 579.23 | 507.77 |
| Other Long Term Assets Total | 250.59 | 156.52 | 138.07 |
| Note Receivable-Long Term | 96.93 | 124.08 | 104.53 |
| Total Current Assets | 5,612.1 | 4,555.86 | 4,259.92 |
| Capital Lease Obligations | 262.28 | 259.92 | 220.42 |
| Accumulated Depreciation Total | Not available | -1,533.89 | -1,307.58 |
| Accrued Expenses | Not available | 199.48 | 193.07 |
| Other Equity Total | Not available | 82.86 | 48.73 |
| Prepaid Expenses | Not available | 89.31 | 94.44 |
| Additional Paid-In Capital | Not available | 785.25 | 9.88 |
| Cash | Not available | 127.41 | 108.4 |
| Property/Plant/Equipment Total-Gross | Not available | 3,836.95 | 3,572.45 |
| Notes Payable/Short Term Debt | Not available | 474.62 | 961.98 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2
Price to Sale Ratio3.97
Growth
Debt 5Yr CAGR %-9.16
Margins
Operating Margin 12m14.12
Operating Margin 5y Avg14.84
Net Profit Margin 12m10.23
Net Profit Margin 5y9.67
Yield
Dividend Yield %0.18
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk33.84
Analyst consensus
ConsensusStrong Buy
Consensus score1.33
Analyst opinions6
Strong Sell count0
Sell count0
Hold count1
Buy count0
Strong Buy count5
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 77.83%
- FII
- 4.87%
- MF
- 6.87%
- Other
- 10.43%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
ICMR Licenses Three Indigenous Health Technologies to Indian Industry - DevdiscourseMarket news · 21 Jul 2026, 8:46 pm
ICMR Licenses Three Indigenous Health Technologies to Indian Industry Devdiscourse
ICMR transfers indigenous cervical cancer drug and vaccine technologies to Emcure and Biological E - BusinessLineMarket news · 21 Jul 2026, 8:17 pm
ICMR transfers indigenous cervical cancer drug and vaccine technologies to Emcure and Biological E BusinessLine
Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026 - marketscreener.comMarket news · 21 Jul 2026, 5:21 pm
Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026 marketscreener.com
Emcure Pharmaceuticals director P.S. Jayakumar ceases to be director - scanx.tradeMarket news · 21 Jul 2026, 4:25 pm
Emcure Pharmaceuticals director P.S. Jayakumar ceases to be director scanx.trade
Emcure Pharma up 3% after CDSCO approves semaglutide for MASH treatment - Business StandardMarket news · 21 Jul 2026, 2:28 pm
Emcure Pharma up 3% after CDSCO approves semaglutide for MASH treatment Business Standard
ICMR transfers three indigenous biomedical technologies - Pharmabiz.comMarket news · 21 Jul 2026, 2:16 pm
ICMR transfers three indigenous biomedical technologies Pharmabiz.com
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.3.6000 per share(36%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Emcure Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active Pharmaceutical Ingredient (APIs). It operates across a wide scope of areas, including Gynecology, Cardiovascular, HIV Antivirals, VMN (Vitamins, Minerals & Nutrients), Pain/Analgesics, Nephrology, Oncology, Anti-Infective, Respiratory, CNS. Its brands include Orofer XT and Pause (Gynecological), Proxym (pain), Tenectase (CNS), Vylda (diabetology), Vitanova (VMN). Its API products include S-Amlodipine, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (Tenecteplase), Vintor (Erythropoietin), TENECTASE (Tenecteplase). It has developed two platforms: Mammalian and Microbial.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- EMCURE
- BSE Code
- 544210
Questions
Stock FAQ
What is the symbol and ISIN of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has the symbol EMCURE and ISIN - INE168P01015.
What is the current price of Emcure Pharmaceuticals?
Emcure Pharmaceuticals is currently trading at INR 1,931.90.
What are the year high and year low of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a year high of INR 2,048.00 and a year low of INR 1,260.00.
What is the market capitalization of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a market capitalization of INR 36,502.25 crore.
What is the P/E ratio of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a P/E ratio of 32.71.
What is the dividend yield of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a dividend yield of 0.18%.
How is the financial performance of Emcure Pharmaceuticals based on revenue, net income, and EPS?
Emcure Pharmaceuticals has revenue of INR 9,203.54 crore, net income of INR 924.36 crore, and EPS of INR 50.00.
What is the book value of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a book value of INR 203.01.
What is the debt-to-equity ratio of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a price-to-book ratio of 9.52 and a price-to-sales ratio of 3.97.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.